What does 3-FOLIA do?

3-FOLIA is a pharmacy in Gent. Private Limited, started on 30 October 2018, 2 establishments.

What is the address of 3-FOLIA?

The registered office of 3-FOLIA is located at Kortrijksesteenweg 1026 box A, 9000 Gent.

Is 3-FOLIA still active?

Yes. According to the CBE (29 October 2026) 3-FOLIA is active, legal situation “Normale toestand”, started on 30 October 2018.

Is 3-FOLIA registered on Peppol?

Yes, 3-FOLIA is registered on the Peppol network with ID 0208:0712690276.

What is the enterprise number of 3-FOLIA?

The enterprise number of 3-FOLIA is BE0712690276.

When was 3-FOLIA founded?

3-FOLIA was founded on 30 October 2018.

Who are the directors of 3-FOLIA?

According to the 2025 annual accounts, the directors of 3-FOLIA are: DETHOSOFT BV, DOKRIPHAR BV.

Is 3-FOLIA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 October 2018; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did 3-FOLIA make in 2025?

3-FOLIA posted a profit after taxes of € 156,896 in financial year 2025.

What is the revenue of 3-FOLIA?

As a small company, 3-FOLIA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 288,415.

How much does an employee at 3-FOLIA earn?

The average wage cost per full-time employee at 3-FOLIA was € 44,700 in 2024: staff costs of € 58,170 for 1.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does 3-FOLIA have?

According to the 2025 annual accounts, 3-FOLIA has 0.8 full-time equivalents (FTE).

3-FOLIA (Private Limited) - Gent - BE0712690276

Dossier 3-FOLIA, printed on 29 October 2026 from databakkes.be/en/0712690276/3-folia. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 1.5 to 0.8.

Financials

Financial year 2025

3-FOLIA from Gent, company number BE0712690276, closed financial year 2025 with a result of € 156,896 after tax. For that financial year 3-FOLIA recorded a gross margin of € 288,415 and equity of € 216,222. Compared with financial year 2024, the result moved from € 180,157 to € 156,896. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.

What it is worth Growing

€ 216,222

▲ 264% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 156,896

▼ 13% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 124,932

▲ 24% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 116,222.

People and assets in 2025

Full-time equivalents

0.8

▼ 0.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 46,573

▼ 20% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt ≈ 1 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 57,502

▼ 33% vs 2024

€ 46,260 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.

Owed to suppliers

€ 145,666

▲ 26% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 8,102

▲ 20% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 82,344 Gross margin 2022: € 82,344 First fiscal year in the series	€ 166,675 Gross margin 2023: € 166,675 ▲ 102% vs 2022 (€ 82,344) Favourable step	€ 294,799 Gross margin 2024: € 294,799 ▲ 77% vs 2023 (€ 166,675) Favourable step	€ 288,415 Gross margin 2025: € 288,415 ▼ 2% vs 2024 (€ 294,799) Unfavourable step	▼ 2%
Profit after taxes	€ -60,042 Profit after taxes 2022: € -60,042 First fiscal year in the series	€ 36,582 Profit after taxes 2023: € 36,582 ▲ € 96,625 vs 2022 (€ -60,042) Favourable step	€ 180,157 Profit after taxes 2024: € 180,157 ▲ € 143,575 vs 2023 (€ 36,582) Favourable step	€ 156,896 Profit after taxes 2025: € 156,896 ▼ 13% vs 2024 (€ 180,157) Unfavourable step	▼ 13%
Equity	€ -157,414 Equity 2022: € -157,414 First fiscal year in the series	€ -120,831 Equity 2023: € -120,831 ▲ € 36,582 vs 2022 (€ -157,414) Favourable step	€ 59,326 Equity 2024: € 59,326 ▲ € 180,157 vs 2023 (€ -120,831) Favourable step	€ 216,222 Equity 2025: € 216,222 ▲ 264% vs 2024 (€ 59,326) Favourable step	▲ 264%
Total debts	€ 738,218 Total debts 2022: € 738,218 First fiscal year in the series	€ 790,632 Total debts 2023: € 790,632 ▲ 7% vs 2022 (€ 738,218) Unfavourable step	€ 595,086 Total debts 2024: € 595,086 ▼ 25% vs 2023 (€ 790,632) Favourable step	€ 480,069 Total debts 2025: € 480,069 ▼ 19% vs 2024 (€ 595,086) Favourable step	▼ 19%
Cash	€ 12,375 Cash 2022: € 12,375 First fiscal year in the series	€ 66,303 Cash 2023: € 66,303 ▲ € 53,928 vs 2022 (€ 12,375) Favourable step	€ 100,928 Cash 2024: € 100,928 ▲ 52% vs 2023 (€ 66,303) Favourable step	€ 124,932 Cash 2025: € 124,932 ▲ 24% vs 2024 (€ 100,928) Favourable step	▲ 24%
Retained profit	€ -257,414 Retained profit 2022: € -257,414 First fiscal year in the series	€ -220,831 Retained profit 2023: € -220,831 ▲ € 36,582 vs 2022 (€ -257,414) Favourable step	€ -40,674 Retained profit 2024: € -40,674 ▲ € 180,157 vs 2023 (€ -220,831) Favourable step	€ 116,222 Retained profit 2025: € 116,222 ▲ € 156,896 vs 2024 (€ -40,674) Favourable step	▲ € 156,896
Bank debt	€ 198,430 Bank debt 2022: € 198,430 First fiscal year in the series	€ 158,905 Bank debt 2023: € 158,905 ▼ 20% vs 2022 (€ 198,430) Favourable step	€ 85,514 Bank debt 2024: € 85,514 ▼ 46% vs 2023 (€ 158,905) Favourable step	€ 57,502 Bank debt 2025: € 57,502 ▼ 33% vs 2024 (€ 85,514) Favourable step	▼ 33%
Balance sheet total	€ 580,805 Balance sheet total 2022: € 580,805 First fiscal year in the series	€ 669,800 Balance sheet total 2023: € 669,800 ▲ 15% vs 2022 (€ 580,805) Unchanged	€ 654,412 Balance sheet total 2024: € 654,412 ▼ 2% vs 2023 (€ 669,800) Unchanged	€ 696,291 Balance sheet total 2025: € 696,291 ▲ 6% vs 2024 (€ 654,412) Unchanged	▲ 6%
Employees (FTE)	1.8 Employees (FTE) 2022: 1.8 First fiscal year in the series	1.5 Employees (FTE) 2023: 1.5 ▼ 0.3 vs 2022 (1.8) Unchanged	1.3 Employees (FTE) 2024: 1.3 ▼ 0.2 vs 2023 (1.5) Unchanged	0.8 Employees (FTE) 2025: 0.8 ▼ 0.5 vs 2024 (1.3) Unchanged	▼ 0.5

Key figures of 3-FOLIA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to 3-FOLIA?

What happened at 3-FOLIA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 1, 2026 New annual accounts for financial year 2025: profit of € 156,896 (▼ 13% vs 2024). Source: NBB ↗
2021 DETHOSOFT BV became a director. NBB
Jan 29, 2020 New establishment in Gent. KBO
Oct 30, 2018 New establishment in Gent. KBO
Oct 30, 2018 Start of the company according to the CBE. KBO
2018 DOKRIPHAR BV became a director. NBB

In short

From € 60,043 loss in 2022 to € 156,896 profit in 2025.

Paid € 41,954 in corporate taxes since 2022.

Best year ever: 2024, with € 180,157 profit.

On average € 226,800 of value added per employee in 2024.

Original PDFs at the National Bank ↗

Management

Dokriphar 45%

DETHOSOFT 45%

The stake of Dokriphar, DETHOSOFT comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

3-FOLIA

Behind 3-FOLIA are DETHOSOFT BV and DOKRIPHAR BV. The shares are held by Dokriphar (45%) and DETHOSOFT (45%).

Directors

According to the 2025 annual accounts

DETHOSOFT BV

Director · represented by Van Nevel Kaatje

since 2021

DOKRIPHAR BV

Director · represented by Simoens Dominiek

Also active at: CASSIPHARMA, DOMICAPHARMA

since 2018

Shareholders

Dokriphar

45%

DETHOSOFT

45%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Kortrijksesteenweg 1026 box A

9000 Gent

2.281.709.422

Buitenring-Sint-Denijs 30

9000 Gent

Active since 30 October 2018

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.

All companies at this address →

Scharnier

ProNuc Nucleaire Geneeskunde

Sensum & Vinum

€ 33,031 gross margin · 2025

Ambrozijn

€ 800,460 gross margin · 2025

Stichting erevoorzitter Jan Steyaert

+1 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0712.690.276
VAT number: BE 0712.690.276
Registered office: Kortrijksesteenweg 1026 bus A, 9000 Gent
Names & denominations: 3-FOLIA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 30 October 2018
Peppol: Active · Active since 7 Oct 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗